| scholarly article | Q13442814 |
| P50 | author | Jelena S Kusic-Tisma | Q84523977 |
| P2093 | author name string | Branko Čalija | |
| Ðorđe Radak | |||
| Dragana Bačković | |||
| Dragica Radojković | |||
| Evgenija Strugarević | |||
| Ljiljana Rakićević | |||
| Mirjana Kovač | |||
| Svetlana Ignjatović | |||
| P2860 | cites work | Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. | Q50946747 |
| Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting | Q56770154 | ||
| Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study | Q58071120 | ||
| Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial | Q84211092 | ||
| Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease | Q87056362 | ||
| [Statin and clopidogrel pharmacological interaction] | Q87175621 | ||
| Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy | Q26852535 | ||
| High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study | Q30450312 | ||
| Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents | Q33335010 | ||
| Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy | Q34019082 | ||
| The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy | Q34397563 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Cytochrome p-450 polymorphisms and response to clopidogrel | Q34910228 | ||
| Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease | Q37259929 | ||
| Pharmacogenomics of clopidogrel: evidence and perspectives | Q37876990 | ||
| The pharmacogenetics of antiplatelet agents: towards personalized therapy? | Q37913976 | ||
| CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis | Q37971875 | ||
| Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? | Q37973457 | ||
| Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists | Q38117748 | ||
| Genetics of platelet inhibitor treatment | Q38131848 | ||
| Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors | Q38177048 | ||
| Antithrombotic therapy in carotid artery stenosis: an update | Q38268760 | ||
| Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogr | Q42857052 | ||
| Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy | Q43057001 | ||
| Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity | Q43643299 | ||
| Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. | Q45947797 | ||
| Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation | Q46784167 | ||
| The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response | Q50199244 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | clopidogrel | Q410237 |
| carotid artery stenosis | Q1576205 | ||
| P304 | page(s) | 26-33 | |
| P577 | publication date | 2015-12-30 | |
| P1433 | published in | Journal of Medical Biochemistry | Q15766602 |
| P1476 | title | Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis | |
| P478 | volume | 35 |
Search more.